Quotient Limited Announces Closing of Underwritten Offering of Ordinary Shares
April 10 2017 - 4:05PM
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics
company, today announced the closing of its underwritten public
offering of 8,050,000 of its ordinary shares at a price to the
public of $6.00 per share, which includes the exercise in full by
the underwriters of their option to purchase up to 1,050,000
additional ordinary shares. The offering generated gross proceeds
of approximately $48.3 million with Quotient receiving net proceeds
of approximately $45.1 million after deducting underwriting
discounts and commissions and other estimated offering expenses
payable by Quotient.
Jefferies LLC acted as sole book-running manager
and BTIG, LLC acted as the lead manager for the offering.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
The securities described above were offered by
Quotient pursuant to a shelf registration statement on Form S-3
that was filed by Quotient with the Securities and Exchange
Commission (SEC) and declared effective on August 17, 2015. Copies
of the final prospectus supplement and accompanying prospectus
relating to this offering may be obtained from Jefferies LLC,
Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd
Floor, New York, NY 10022, or by telephone at (877) 821-7388 or by
email at Prospectus_Department@Jefferies.com; and BTIG, LLC, Equity
Capital Markets, 825 Third Avenue, New York, NY 10022, or by
telephone at (212) 593-7555 or by email at
EquityCapitalMarkets@btig.com.
About Quotient Limited
Quotient is a commercial-stage diagnostics
company committed to reducing healthcare costs and improving
patient care through the provision of innovative tests within
established markets. With an initial focus on blood grouping and
serological disease screening, Quotient is developing its
proprietary MosaiQ™ technology platform to offer a breadth of tests
that is unmatched by existing commercially available transfusion
diagnostic instrument platforms. The company's operations are based
in Edinburgh, Scotland; Eysins, Switzerland and Newtown,
Pennsylvania.
The Quotient logo and MosaiQ™ are registered
trademarks or trademarks of Quotient Limited and its subsidiaries
in various jurisdictions.
CONTACT: Christopher Lindop, Chief Financial Officer — christopher.lindop@quotientbd.com; +41 22-545-5226
Quotient (NASDAQ:QTNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Quotient (NASDAQ:QTNT)
Historical Stock Chart
From Apr 2023 to Apr 2024